Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danish biotechnology company NsGene has said that its clinical trial application to start a Phase Ib study of NsG0202 for Alzheimer's disease has been approved by the Swedish Medical Products Agency.
Subscribe to our email newsletter
NsG0202 consists of an implantable encapsulated cell (EC) biodelivery device that secretes nerve growth factor (NGF). NGF has shown to have neuroprotective and regenerative effects when delivered to relevant areas of the brain. NsG0202 is aimed at treating the progressive dementia associated with AD. It is expected that the initial three patients will have the EC biodelivery device implanted in the beginning of 2008. In all, six patients will participate in this Phase Ib study, which will run for one year.
Teit Johansen, president & CEO of NsGene, said: “This landmark achievement brings NsGene a step closer to a breakthrough for a treatment of this devastating disease and, by entering the clinic, the company has risen to the next level of corporate development including partnering opportunities for a maximal exploitation of our NsG0202 product.”